BioGend Therapeutics Co., Ltd.

BioGend Therapeutics Co., Ltd. is a biotechnology company specializing in the research, development, and commercialization of advanced orthopedic medical equipment and related healthcare products. Founded in 2016 and headquartered in Taipei, Taiwan, the company focuses on innovative solutions for bone and cartilage repair, particularly for orthopedic and musculoskeletal conditions. Key products under development include BiG-001 and BiG-006, which are osteoinductive bone graft substitutes engineered to enhance bone regeneration, as well as BiG-009, an autologous cartilage repair system designed to facilitate healing of cartilage defects using the patient’s own cells. Operating within the healthcare sector, BioGend Therapeutics plays a significant role in introducing new medical technologies that impact both clinical practices and patient outcomes in orthopedics. Its work supports advancements in surgical procedures, rehabilitation, and regenerative medicine, contributing to the dynamic growth of the biotechnology and medical research industry in Taiwan and beyond.